Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Media Resources

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Probuphine(R) Patent Issued by the U.S. Patent and Trademark Office

June 16, 2010

Titan Stock Commences Trading on the OTCBB

June 2, 2010

Titan Pharmaceuticals Announces First Quarter 2010 Financial Results

May 17, 2010

Titan Announces Completion of Re-Registration of the Company With the Securities and Exchange Commission

April 27, 2010

Titan Provides Estimate of Upcoming Royalty Payment

April 21, 2010

Titan Initiates Confirmatory Phase 3 Study of Probuphine(R) in the Treatment of Opioid Addiction

March 30, 2010

Titan Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

February 4, 2010

Titan Pharmaceuticals Files Form 10 for Re-registration of the Company With the Securities and Exchange Commission

January 19, 2010

Titan Pharmaceuticals to Receive $3 Million Loan

December 21, 2009

Titan Receives Notice of Allowance for Probuphine(R) Patent Application in the Treatment of Opiate Addiction

November 30, 2009

  • « Previous
  • 1...
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • Next »
© 2025 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter